Patents by Inventor Abbott GmbH & Co.KG

Abbott GmbH & Co.KG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
    Publication number: 20130324537
    Abstract: The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
    Type: Application
    Filed: November 21, 2012
    Publication date: December 5, 2013
    Applicants: Abbott Laboratories, Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co. KG, Abbott Laboratories, Andrea Hager-Wernet
  • NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE
    Publication number: 20130317044
    Abstract: Carboxylic acid derivatives where R—R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
    Type: Application
    Filed: November 27, 2012
    Publication date: November 28, 2013
    Applicant: Abbott Gmbh & Co. KG
    Inventor: Abbott Gmbh & Co. KG
  • ABETA CONFORMER SELECTIVE ANTI-ABETA GLOBULOMER MONOCLONAL ANTIBODIES
    Publication number: 20130287799
    Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
    Type: Application
    Filed: April 15, 2013
    Publication date: October 31, 2013
    Inventors: Abbott Laboratories, Abbott GmbH & Co. KG
  • ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF
    Publication number: 20130149313
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ? and advanced glycation-end-products.
    Type: Application
    Filed: November 27, 2012
    Publication date: June 13, 2013
    Applicants: ABBOTT LABORATORIES, ABBOTT GMBH & CO. KG
    Inventors: ABBOTT GMBH & CO. KG, ABBOTT LABORATORIES
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20130116241
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: October 25, 2012
    Publication date: May 9, 2013
    Applicants: AbbVie Inc., Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co. KG, AbbVie Inc.
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20130116229
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: November 8, 2012
    Publication date: May 9, 2013
    Applicants: AbbVie Inc., Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co.KG, AbbVie Inc.
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20130116233
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: October 29, 2012
    Publication date: May 9, 2013
    Applicants: AbbVie Inc., Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co. KG, AbbVie Inc.